We value your privacy

We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. The Administrator of personal data is STOCKTRADEIQ sp. z o.o., with its registered office in Poznan (61-625), at the following address: Czarna Rola 30 Street. Cookies policy here. By clicking "Accept All", you consent to our use of cookies.

Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

  • Cookie
    cookieyes-consent
  • Duration
    1 year
  • Description
    CookieYes sets this cookie to remember users' consent preferences so that their preferences are respected on their subsequent visits to this site. It does not collect or store any personal information of the site visitors.
  • Cookie
    x-ms-cpim-csrf
  • Duration
    session
  • Description

    Inter-site request forgery token used to protect crSF. For more information, read the section Token falsification of requests between sites.

  • Cookie
    x-ms-cpim-sso:stocktradeiqauth.onmicrosoft.com_0
  • Duration
    session
  • Description

    Used to support single sign-on sessions. This cookie is set as persistent when the Keep me logged in option is enabled.

  • Cookie
    server-telemetry-{id}
  • Duration
    persistent
  • Description

    A value used by Microsoft for authorisation and authentication.

  • Cookie
    google_auto_fc_cmp_setting
  • Duration
    persistent
  • Description


    Stores the state of the User cookie for the current domain.

     

  • Cookie
    {id}-https://stocktradeiqauth.onmicrosoft.com/{id}
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    msal{id}.active-account
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-refreshtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com-idtoken
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    {id}signinup{id}stocktradeiqauth.b2clogin.com
  • Duration
    persistent
  • Description

    Stores information about the logged-in user's session.

  • Cookie
    Microsoft Clarity
  • Duration
    1 year
  • Description

    Microsoft Clarity

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

  • Cookie
    isLightMode
  • Duration
    1 year
  • Description

    Defines the UI theme

  • Cookie
    userCultureData
  • Duration
    persistent
  • Description

     Stores information about the user's machine culture.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

  • Cookie
    _ga
  • Duration
    1 year 1 month 4 days
  • Description
    The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognize unique visitors.
  • Cookie
    _ga_*
  • Duration
    1 year 1 month 4 days
  • Description
    Google Analytics sets this cookie to store and count page views.
  • Cookie
    hotjar
  • Duration
    1 year 1 month 4 days
  • Description

    Analyzing users' behaviour in the website

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

  • Cookie
    __gpi
  • Duration
    1 year 24 days
  • Description
    Google Ads Service uses this cookie to collect information about from multiple websites for retargeting ads.
  • Cookie
    __gads
  • Duration
    1 year 24 days
  • Description

    The file, set by Google, is stored in the DoubleClick domain and tracks the number of times users view an ad, measures the success of the campaign and calculates its revenue. This cookie can only be read from the domain where it is set and does not track any data when browsing other sites.

  • Cookie
    goog:cached:topics
  • Duration
    persistent
  • Description

    It is used to record which adverts have been displayed to the User.

  • Cookie
    IDE
  • Duration
    year
  • Description

    Used by Google DoubleClick to record and report on the Website User's actions after viewing or clicking on an advertiser's ads in order to measure the effectiveness of the ad and present the User with targeted advertising.

  • Cookie
    google_experiment_mod44
  • Duration
    persistent
  • Description

    Used by Google Ad to experiment with the effectiveness of ads on websites using their services.

Powered by Cookieyes logo

    Get Diamond plan for FREE

    logo

    Integra LifeSciences Holdings Corporation (IART)

    Price:

    14.86 USD

    ( + 1.18 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    IART
    Name
    Integra LifeSciences Holdings Corporation
    Industry
    Medical - Devices
    Sector
    Healthcare
    Price
    14.860
    Market Cap
    1.158B
    Enterprise value
    3.485B
    Currency
    USD
    Ceo
    Mojdeh Poul
    Full Time Employees
    4396
    Website
    integralife.com
    Ipo Date
    1995-08-16
    City
    Princeton
    Address
    1100 Campus Road

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    iRhythm Technologies, Inc.

    VALUE SCORE:

    5

    Symbol
    IRTC
    Market Cap
    5.449B
    Industry
    Medical - Devices
    Sector
    Healthcare

    2nd position

    PROCEPT BioRobotics Corporation

    VALUE SCORE:

    9

    Symbol
    PRCT
    Market Cap
    2.290B
    Industry
    Medical - Devices
    Sector
    Healthcare

    The best

    Viemed Healthcare, Inc.

    VALUE SCORE:

    11

    Symbol
    VMD
    Market Cap
    282.748M
    Industry
    Medical - Devices
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    -2.270
    P/S
    0.714
    P/B
    1.094
    Debt/Equity
    1.939
    EV/FCF
    -308.664
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    1.821
    Earnings yield
    -0.441
    Debt/assets
    0.549
    FUNDAMENTALS
    Net debt/ebidta
    -4.860
    Interest coverage
    -12.337
    Research And Developement To Revenue
    0.068
    Intangile to total assets
    0.492
    Capex to operating cash flow
    1.160
    Capex to revenue
    0.043
    Capex to depreciation
    0.941
    Return on tangible assets
    -0.269
    Debt to market cap
    1.739
    Piotroski Score
    5.000
    FUNDAMENTALS
    PEG
    0.001
    P/CF
    19.055
    P/FCF
    -120.990
    RoA %
    -13.649
    RoIC %
    -13.328
    Gross Profit Margin %
    52.602
    Quick Ratio
    0.729
    Current Ratio
    1.229
    Net Profit Margin %
    -30.870
    Net-Net
    -25.237
    FUNDAMENTALS PER SHARE
    FCF per share
    -0.125
    Revenue per share
    21.209
    Net income per share
    -6.547
    Operating cash flow per share
    0.780
    Free cash flow per share
    -0.125
    Cash per share
    3.317
    Book value per share
    13.584
    Tangible book value per share
    -10.016
    Shareholders equity per share
    13.584
    Interest debt per share
    26.867
    TECHNICAL
    52 weeks high
    27.130
    52 weeks low
    11.060
    Current trading session High
    15.170
    Current trading session Low
    13.840
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0.0056274305%
    Payout Ratio
    38.190954999999995%
    P/E
    67.687
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0.014269152%
    Payout Ratio
    22.420052%
    P/E
    15.746
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Instruments & Supplies
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    16.645
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Instruments & Supplies
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -85.539
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    46.955
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Instruments & Supplies
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    44.338
    logo
    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -4.670
    DESCRIPTION

    Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

    NEWS
    https://images.financialmodelingprep.com/news/integra-lifesciences-holdings-corporation-iart-q2-2025-earnings-call-20250801.jpg
    Integra LifeSciences Holdings Corporation (IART) Q2 2025 Earnings Call Transcript

    seekingalpha.com

    2025-08-01 13:56:42

    Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Executives Christopher Ward – Senior Director of Investor Relations Lea Daniels Knight – Executive VP & CFO Mojdeh Poul – President, CEO & Director Analysts Lilia-Celine Breton Lozada - JPMorgan Chase & Co, Research Division Ravi Misra - Truist Securities, Inc., Research Division Unknown Analyst Vikramjeet Singh Chopra - Wells Fargo Securities, LLC, Research Division Xuyang Li - Jefferies LLC, Research Division Operator Good day, and thank you for standing by. Welcome to the Integra LifeSciences Second Quarter 2025 Financial Results Call.

    https://images.financialmodelingprep.com/news/integra-iart-q2-revenue-beats-by-5-20250731.jpg
    Integra (IART) Q2 Revenue Beats by 5%

    fool.com

    2025-07-31 23:53:11

    Integra (IART) Q2 Revenue Beats by 5%

    https://images.financialmodelingprep.com/news/compared-to-estimates-integra-iart-q2-earnings-a-look-at-20250731.jpg
    Compared to Estimates, Integra (IART) Q2 Earnings: A Look at Key Metrics

    zacks.com

    2025-07-31 10:36:23

    Although the revenue and EPS for Integra (IART) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

    https://images.financialmodelingprep.com/news/integra-lifesciences-iart-beats-q2-earnings-and-revenue-estimates-20250731.jpg
    Integra LifeSciences (IART) Beats Q2 Earnings and Revenue Estimates

    zacks.com

    2025-07-31 08:11:12

    Integra LifeSciences (IART) came out with quarterly earnings of $0.45 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to earnings of $0.63 per share a year ago.

    https://images.financialmodelingprep.com/news/integra-lifesciences-reports-second-quarter-2025-financial-results-20250731.jpg
    Integra LifeSciences Reports Second Quarter 2025 Financial Results

    globenewswire.com

    2025-07-31 06:00:00

    PRINCETON, N.J., July 31, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2025.

    https://images.financialmodelingprep.com/news/integra-lifesciences-to-host-second-quarter-2025-financial-results-conference-20250714.jpg
    Integra LifeSciences to Host Second Quarter 2025 Financial Results Conference Call on July 31, 2025

    globenewswire.com

    2025-07-14 16:35:00

    PRINCETON, N.J., July 14, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release second quarter 2025 financial results on Thursday, July 31, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.

    https://images.financialmodelingprep.com/news/iart-stock-may-rise-on-first-enrollment-in-aera-20250703.jpg
    IART Stock May Rise on First Enrollment in AERA Pediatric Registry

    zacks.com

    2025-07-03 10:26:04

    Integra enrolls first pediatric patient in AERA registry to evaluate real-world use of its ETBD system and expand ENT market presence.

    https://images.financialmodelingprep.com/news/integra-lifesciences-announces-first-patient-enrolled-in-acclarent-aera-20250702.jpg
    Integra LifeSciences Announces First Patient Enrolled in Acclarent AERA® Pediatric Registry

    globenewswire.com

    2025-07-02 16:09:00

    PRINCETON, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holding Corporation (Nasdaq: IART), a leading global medical technology company, is proud to announce enrollment of the first patient in the Acclarent AERA Pediatric Registry, a prospective, multi-center observational registry evaluating the real-world use of the AERA Eustachian Tube Balloon Dilation System in children.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-integra-20250622.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

    prnewswire.com

    2025-06-22 10:00:00

    NEW YORK , June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claimson-behalf-of-investors-of-integra-lifesciences-20250618.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

    globenewswire.com

    2025-06-18 12:35:00

    NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-integra-20250617.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

    prnewswire.com

    2025-06-17 10:00:00

    NEW YORK , June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-integra-lifesciences-20250616.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

    accessnewswire.com

    2025-06-16 17:15:00

    NEW YORK CITY, NY / ACCESS Newswire / June 16, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claimson-behalf-of-investors-of-integra-20250615.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

    globenewswire.com

    2025-06-15 10:00:00

    NEW YORK, June 15, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com  or 646-581-9980, ext. 7980.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-integra-20250613.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

    accessnewswire.com

    2025-06-13 09:15:00

    NEW YORK CITY, NY / ACCESS Newswire / June 13, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-integra-20250612.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

    prnewswire.com

    2025-06-12 09:00:00

    NEW YORK , June 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ: IART).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

    https://images.financialmodelingprep.com/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-integra-20250611.jpg
    INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Integra LifeSciences Holdings Corporation - IART

    accessnewswire.com

    2025-06-11 09:00:00

    NEW YORK CITY, NY / ACCESS Newswire / June 11, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Integra LifeSciences Holdings Corporation ("Integra" or the "Company") (NASDAQ:IART). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.